Home › Burkitt Lymphoma › Wisconsin
Burkitt Lymphoma clinical trials in Wisconsin
16 studies for Burkitt Lymphoma are looking for participants at sites in Wisconsin.
Cities in Wisconsin
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- Marshfield Medical Center-Marshfield, Marshfield
- Froedtert Menomonee Falls Hospital, Menomonee Falls
- and 8 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03739814A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Children's Hospital of Wisconsin, Milwaukee
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Nov 12, 2026 · NCT04546399Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- and 1 more
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Nov 3, 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Wisconsin, Milwaukee
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Children's Hospital of Wisconsin, Milwaukee
RecruitingPhase 2
365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Children's Hospital of Wisconsin, Milwaukee
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 27, 2026 · NCT06124157Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Medical College of Wisconsin, Milwaukee
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Milwaukee
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 13, 2026 · NCT06137118Blinatumomab Consolidation in Real World
- Medical College of Wisconsin, Milwaukee
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07117136Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Medical College of Wisconsin, Milwaukee
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- and 1 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
- Froedtert & the Medical College of Wisconsin, Milwaukee
RecruitingPhase 1
Ages 18 to 81 · All sexes · Updated Aug 6, 2026 · NCT05990465MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
- Children's Wisconsin, Milwaukee
Recruiting
Ages 0 to 25 · All sexes · Updated May 13, 2026 · NCT05794880Study of SGR-1505 in Mature B-Cell Neoplasms
- Medical College of Wisconsin, Milwaukee
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
RecruitingObservational study
Ages 18 to 80 · All sexes · Updated Nov 10, 2025 · NCT03375619Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
- Children's Hospital of Wisconsin, Milwaukee
RecruitingPhase 2
Up to age 25 · All sexes · Updated Sep 17, 2021 · NCT04746209From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.